Cargando…

Genetic modifiers of fetal hemoglobin affect the course of sickle cell disease in patients treated with hydroxyurea

The course of sickle cell disease (SCD) is modified by polymorphisms boosting fetal hemoglobin (HbF) synthesis. However, it has remained an open question how these polymorphisms affect patients who are treated with the HbF-inducing drug hydroxyurea/ hydroxycarbamide. The German SCD registry offers t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Allard, Pierre, Alhaj, Nareen, Lobitz, Stephan, Cario, Holger, Jarisch, Andreas, Grosse, Regine, Oevermann, Lena, Hakimeh, Dani, Tagliaferri, Laura, Kohne, Elisabeth, Kopp-Schneider, Annette, Kulozik, Andreas E., Kunz, Joachim B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2021
Materias:	Article - Hemoglobinopathies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244815/ https://www.ncbi.nlm.nih.gov/pubmed/34706496 http://dx.doi.org/10.3324/haematol.2021.278952

Ejemplares similares

Benefits of a Disease Management Program for Sickle Cell Disease in Germany 2011–2019: The Increased Use of Hydroxyurea Correlates with a Reduced Frequency of Acute Chest Syndrome
por: Kunz, Joachim B., et al.
Publicado: (2021)

Introduction of Universal Newborn Screening for Sickle Cell Disease in Germany—A Brief Narrative Review
por: Lobitz, Stephan, et al.
Publicado: (2021)

P1480: SPLENIC SEQUESTRATION IS MORE COMMON IN SCD-S/Β0-THAL THAN IN SCD-S/S PATIENTS: RESULTS FROM THE GERMAN SCD REGISTRY
por: Allard, P., et al.
Publicado: (2022)

Sickle Cell Disease in Africa: A Neglected Cause of Early Childhood Mortality
por: Grosse, Scott D., et al.
Publicado: (2011)

5613004 NEWBORN SCREENING FOR SICKLE CELL DISEASE IN GERMANY - THE FIRST YEAR
por: Lobitz, S., et al.
Publicado: (2023)

The Effects of Treatment with Blood Transfusion, Iron Chelation and Hydroxyurea on Puberty, Growth and Spermatogenesis in Sickle Cell Disease (SCD): A short update
por: Soliman, Ashraf T, et al.
Publicado: (2021)

Transition in Sickle Cell Disease (SCD): A German Consensus Recommendation
por: Alashkar, Ferras, et al.
Publicado: (2022)

Outcomes of Sickle Cell Disorders in COVID-19 Infection: An Institutional Experience
por: Sewaralthahab, Sarah, et al.
Publicado: (2020)

Hospitalization and Case Fatality in Individuals with Sickle Cell Disease and COVID-19 Infection
por: Mucalo, Lana, et al.
Publicado: (2020)

Candidate Sequence Variants and Fetal Hemoglobin in Children with Sickle Cell Disease Treated with Hydroxyurea
por: Green, Nancy S., et al.
Publicado: (2013)

Impact of Sickle Cell Trait on Morbidity and Mortality from Sars-Cov-2 Infection
por: Merz, Lauren E., et al.
Publicado: (2020)

Healthcare Utilization Among Children and Adolescents with Sickle Cell Disease during the COVID-19 Pandemic
por: Nowlin, Andrea, et al.
Publicado: (2020)

Actions of L-Glutamine vs. COVID-19 Suggest Additional Benefit in Sickle Cell Disease
por: Abdelaal, Mahmoud A.Z., et al.
Publicado: (2020)

Sickle Cell Disease Related Outcomes in Patients Evaluated for COVID-19 Infections in South Carolina
por: Noisette, Laurence, et al.
Publicado: (2020)

Venous Thromboembolism Prophylaxis Practices for Patients with Sickle Cell Disease Pre and during the COVID-19 Pandemic
por: Davila, Jennifer G., et al.
Publicado: (2020)

Heterogeneity of βs gene haplotypes in patients with sickle cell disease (SCD) in Oman: A review of relevant publications
por: Al-Mashaikhi, Nawal, et al.
Publicado: (2022)

COVID-19 in Hospitalized Patients with Sickle Cell Disease
por: Guarino, Stephanie, et al.
Publicado: (2021)

Identification of the Pitfalls in the Attempted Use of Extracorporeal Membrane Oxygenation in an Adult Patient with Sickle Cell Disease and Severe Acute Chest Syndrome
por: Tanenbaum, Mira T, et al.
Publicado: (2019)

Blood transfusion and iron overload in patients with Sickle Cell Disease (SCD): Personal experience and a short update of diabetes mellitus occurrence
por: Soliman, Ashraf T, et al.
Publicado: (2022)

COVID-19 Infection and Outcomes at a Comprehensive Sickle Cell Center
por: El Rassi, Fuad, et al.
Publicado: (2021)

Hydroxyurea Treatment for Sickle Cell Disease
por: Steinberg, Martin H.
Publicado: (2002)

Sickle Cell Disease and COVID-19 Infection: A Single-Center Experience
por: Devarashetty, Sindhu, et al.
Publicado: (2021)

Impact of the COVID-19 Pandemic on Acute Care Visits for Patients with Sickle Cell Disease
por: Orkoulas-Razis, Dennis, et al.
Publicado: (2021)

Whole Exome Sequencing Identifies Novel Genes for Fetal Hemoglobin Response to Hydroxyurea in Children with Sickle Cell Anemia
por: Sheehan, Vivien A., et al.
Publicado: (2014)

Hydroxyurea-Increased Fetal Hemoglobin Is Associated with Less Organ Damage and Longer Survival in Adults with Sickle Cell Anemia
por: Fitzhugh, Courtney D., et al.
Publicado: (2015)

Excess All-Cause Mortality in 2020 for People Living with Sickle Cell Disease in New York City
por: Curtis, Susanna A, et al.
Publicado: (2021)

Incidence of Sars-COV-2 Infection in Sickle Cell Patients Presenting with a Painful Crisis, a 12 Month Prospective Cohort Study
por: Konté, Kadère, et al.
Publicado: (2021)

Hydroxyurea and sickle cell anemia: effect on quality of life
por: Ballas, Samir K, et al.
Publicado: (2006)

Effective control of sickle cell disease with hydroxyurea therapy
por: Singh, Harminder, et al.
Publicado: (2010)

The influence of hydroxyurea on oxidative stress in sickle cell anemia
por: Torres, Lidiane de Souza, et al.
Publicado: (2012)

Evaluation of hydroxyurea genotoxicity in patients with sickle cell disease
por: de Oliveira, Emanuel Almeida Moreira, et al.
Publicado: (2019)

Whole Blood Adhesion to VCAM-1 and P-Selectin and RBC Mechanical Fragility Can be Compromised in Long COVID-19 Patients with Sickle Cell Disease
por: Tarasev, Michael, et al.
Publicado: (2021)

P102: PLASMA FREE HEMOGLOBIN AND REACTIVE OXYGEN SPECIES IN SICKLE CELL ANAEMIA PATIENTS UNDER HYDROXYUREA AND GLUTAMINE THERAPY
por: Giannaki, A, et al.
Publicado: (2022)

ENHANCE—(Electronic Hydroxyurea Adherence): A Protocol to Increase Hydroxyurea Adherence in Patients with Sickle Cell Disease
por: Creary, Susan, et al.
Publicado: (2016)

The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea
por: da Silva, Luiz Bernardino Lima, et al.
Publicado: (2012)

Comment on "The influence of hydroxyurea on oxidative stress in sickle cell anemia"
por: van Beers, Eduard Johannes, et al.
Publicado: (2012)

Emerging Science of Hydroxyurea Therapy for Pediatric Sickle Cell Disease
por: Green, Nancy S., et al.
Publicado: (2013)

Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia
por: Keikhaei, Bijan, et al.
Publicado: (2016)

Concurrent use of hydroxyurea and deferasirox in Californians with sickle cell disease
por: Wong, Trisha E., et al.
Publicado: (2021)

Mathematical Modeling of Hydroxyurea Therapy in Individuals with Sickle Cell Disease
por: Pandey, Akancha, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_71ma696v9r1jieqijhfv0simpt